Bridgeway Capital Management LLC Has $530,000 Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Bridgeway Capital Management LLC grew its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 5.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,072 shares of the company’s stock after purchasing an additional 3,305 shares during the period. Bridgeway Capital Management LLC owned about 0.19% of iTeos Therapeutics worth $530,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ITOS. Virtus ETF Advisers LLC lifted its stake in iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after buying an additional 3,293 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of iTeos Therapeutics during the fourth quarter valued at approximately $96,000. SG Americas Securities LLC lifted its position in shares of iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after acquiring an additional 1,508 shares in the last quarter. Marquette Asset Management LLC acquired a new position in iTeos Therapeutics in the 4th quarter worth approximately $122,000. Finally, Wells Fargo & Company MN grew its position in iTeos Therapeutics by 16.9% during the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after purchasing an additional 2,402 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Wall Street Analysts Forecast Growth

ITOS has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th. JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Finally, Wells Fargo & Company dropped their target price on iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th.

iTeos Therapeutics Trading Down 0.3%

NASDAQ ITOS opened at $6.68 on Monday. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $18.70. The firm’s fifty day simple moving average is $6.55 and its 200-day simple moving average is $7.44. The company has a market capitalization of $255.67 million, a PE ratio of -2.12 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.